Edition:
United Kingdom

Profile: Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

5.95USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$5.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,586
52-wk High
$14.70
52-wk Low
$3.07

Aravive, Inc., formerly Versartis, Inc., incorporated on December 10, 2008, is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.

The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc-fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Company Address

Aravive Inc

1221 McKinney St Ste 3200
HOUSTON   TX   77010-2033
P: +1936.3551910
F: +1302.5313150

Company Web Links